Sage Therapeutics Inc (NASDAQ:SAGE) — Market Cap & Net Worth
Market Cap & Net Worth: Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (NASDAQ:SAGE) has a market capitalization of $544.94 Million ($544.94 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11848 globally and #3000 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sage Therapeutics Inc's stock price $8.68 by its total outstanding shares 62781400 (62.78 Million). Also see Sage Therapeutics Inc total assets for a full breakdown of the balance sheet.
Sage Therapeutics Inc Market Cap History: 2015 to 2025
Sage Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $3.66 Billion to $544.94 Million (-15.82% CAGR). Also see SAGE cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Sage Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #324 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1183 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #181 of 263 |
Weight: Sage Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sage Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sage Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Sage Therapeutics Inc (SAGE) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.27x
Sage Therapeutics Inc's market cap is 8.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $6.01 Billion | $90.27 Million | -$372.88 Million | 66.62x | N/A |
| 2019 | $4.53 Billion | $6.87 Million | -$650.15 Million | 659.90x | N/A |
| 2020 | $5.43 Billion | $1.11 Billion | $606.07 Million | 4.87x | 8.96x |
| 2021 | $2.67 Billion | $6.31 Million | -$450.83 Million | 423.39x | N/A |
| 2022 | $2.39 Billion | $7.69 Million | -$503.27 Million | 311.54x | N/A |
| 2023 | $1.36 Billion | $86.45 Million | -$541.49 Million | 15.74x | N/A |
| 2024 | $340.90 Million | $41.24 Million | -$400.67 Million | 8.27x | N/A |
Competitor Companies of SAGE by Market Capitalization
Companies near Sage Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review SAGE goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sage Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Sage Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Sage Therapeutics Inc's market cap moved from $3.66 Billion to $ 544.94 Million, with a yearly change of -15.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $544.94 Million | +59.85% |
| 2024 | $340.90 Million | -74.94% |
| 2023 | $1.36 Billion | -43.18% |
| 2022 | $2.39 Billion | -10.34% |
| 2021 | $2.67 Billion | -50.83% |
| 2020 | $5.43 Billion | +19.84% |
| 2019 | $4.53 Billion | -24.64% |
| 2018 | $6.01 Billion | -41.84% |
| 2017 | $10.34 Billion | +222.58% |
| 2016 | $3.21 Billion | -12.42% |
| 2015 | $3.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 30th, 2026 the market cap of Sage Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $544.94 Million USD |
| MoneyControl | $544.94 Million USD |
| MarketWatch | $544.94 Million USD |
| marketcap.company | $544.94 Million USD |
| Reuters | $544.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sage Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric m… Read more